Validation Analyst 1

Driving Quality Culture to Manage Risk: lessons from an FDA inspection response. At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture. At the 2026 PDA/FDA Joint Regulatory Conference, B. Timothy Bassler, SVP of Quality Operations at PCI Pharma Services, presented "Driving Quality Culture to Manage Risk," using a real-world FDA inspection case study to illustrate how quality culture and quality management systems (QMS) work together to manage compliance risk.[1] His framing message: complexity is the enemy of compliance. Bassler opened by outlining what active, visible quality oversight looks like in practice: routine presence on the shop floor, timely review of microbiological signals, willingness to challenge weak investigations, oversight of aseptic behaviors, and escalation of unresolved risks. He emphasized that a quality unit needs sufficient authority, technical expertise, staffing, and independence to act, including the authority to halt operations when sterility assurance may be compromised. That expectation tracks with how Siegfried Schmitt has to PharmTech: it's the function that implements and owns the pharmaceutical quality system underpinning a site's compliance, separate from, and independent of, the operations it oversees. The presentation's centerpiece was a case study drawn from PCI's May 2025 acquisition of Ajinomoto Althea's San Diego-based sterile fill-finish site.[2] Shortly after the acquisition closed, an FDA inspection at the site concluded on May 9, 2025, resulting in a Form 483 with multiple observations and triggering a formal remediation response.[3] Bassler walked through the subsequent timeline: a July 2025 leadership meeting between FDA's Office of Manufacturing Quality and senior PCI leadership, voluntary commitments to remediate additional observations identified during that dialogue, the agency's issuance of Voluntary Action Indicated status, and ongoing status updates to FDA through completion of all committed actions. The remediation path Bassler described mirrors the pitfalls discussed during, when agency officials warned that companies too often propose quick fixes without thorough root-cause analysis instead of the comprehensive remediation that FDA expects. A key theme of Bassler's presentation was FDA's expectation that companies bring in third-party expertise to strengthen quality unit oversight, spanning audits of aseptic processing design, independent assessment of quality unit functions, and review of investigation systems for deviations, discrepancies, complaints, and out-of-specification results. Warning letters citing after repeated aseptic-line failures have shown how quickly weak investigation systems escalate into agency action. To operationalize FDA's feedback, PCI conducted a comprehensive site quality unit assessment combining document review, personnel interviews, a "voice of customer" survey, walkthroughs, mock disposition exercises, and trend analysis of quality metrics. That assessment produced seven defined actions across three workstreams: governance and authority, operational control, and capability-building for quality unit personnel. Bassler detailed several resulting system improvements: an integrated batch disposition model embedding quality checkpoints throughout the batch lifecycle, an aseptic core monitor program providing real-time observation and peer-to-peer feedback on aseptic operations, a risk-tiered aseptic qualification framework, and a formal quality authority and decision-making matrix assigning investigation decision rights by role and risk. Bassler closed with three takeaways: conduct a detailed current-state assessment before acting, set explicit expectations to drive process improvement, and track data continuously to sustain gains. The presentation credited PCI's San Diego Development and Manufacturing team, PricewaterhouseCoopers Advisory Services, and Network Partners Group for their roles in the remediation effort. References

Atsushi Watanabe to become president of PCI Holdings May 20, 2026 17:59 Atsushi Watanabe: Graduated from Shinshu University's Faculty of Economics in 1986 (Showa 61). Joined Kyodo VAN (now SCSK). Became president of SCSK Serviceware in 2022 and director of Lester in April 2026. Born in Hyogo Prefecture. Aged 64. (Will become president on June 23. Current president Kensaku Morishita will become senior managing director) All articles freely readable Paid members get first month free AI trained on Nikkei online edition articles

PCI Pharma Services makes $1B investment to scale injectable manufacturing, device assembly. By Pharma Manufacturing - Facilities - April 29, 2026 - 5 min Philadelphia-based PCI Pharma Services, a global contract development and manufacturing organization (CDMO), has announced a series of infrastructure investments aimed at expanding its sterile fill-finish and advanced drug delivery capabilities, as demand for injectable therapies and supply chain resilience continues to reshape the pharmaceutical industry. The investments are part of a broader commitment exceeding $1 billion across PCI's U.S. and European operations, meant to reinforce the CDMO's ability to support drug product development and manufacturing, clinical trial supply, and drug-device combination assembly from clinical stages through commercial launch. Central to the announcement is a $100 million investment at PCI's San Diego campus, where the company will install a high-speed isolator filling line for ready-to-use (RTU) prefilled syringes and cartridges. The new line, expected to be operational in the first half of 2028, will more than double the site's existing syringe and cartridge capacity, which already supports more than 45 FDA-approved products. The San Diego campus also hosts large-scale aseptic filling for prefilled syringes and cartridges, alongside specialized capabilities in oligonucleotides, peptides, complex formulations, and lyophilization for injectables such as nanoparticles, mRNA, monoclonal antibodies, proteins, and highly potent products. Chief Commercial Officer Tim Roberts told Pharma Manufacturing these investments reflect a broader shift toward injectable drug formats, driven in part by the rapid rise of GLP-1 therapies and other biologics that are increasingly administered outside traditional healthcare settings. This trend is also extending into more complex therapeutic areas, including oncology and central nervous system (CNS) disorders, making drug-device combinations more central to how therapies are developed and delivered, according to Roberts. "Now those next-generation medicines for oncology, CNS, and rare diseases no longer need to be delivered strictly by healthcare professionals," says Roberts. "That accepted technology of pens, autoinjectors, and on-body devices is now being recognized by pharma companies and payers as the forward modality of how these lifesaving medicines can be delivered in a much more patient-centric way." In parallel, PCI's Bedford, New Hampshire site is commissioning a GMP-ready isolator vial and lyophilization line capable of producing batches of up to 300,000 vials at 400 units per minute - equating to approximately 33 million units annually - following the start of full-scale production in April. The campus will also bring online a customer-dedicated high-potent sterile fill-finish line, according to the company. Both sites are also being outfitted with advanced automated visual inspection (AVI) systems for sterile fill-finish applications. According to Roberts, these systems enhance defect detection - including particulates and cosmetic issues - while enabling rapid, highly accurate inspection of both containers and drug products, helping expand capacity without compromising quality. PCI's U.S.-based AVI infrastructure includes annual accommodation for 40 million blister units, 70 million bottles, and 75 million vials. "It can do these things very quickly and very accurately," Roberts said of the AVI systems. "In investing in AVI systems to this degree, PCI is furthering its ability to have ample room without sacrificing mission-critical quality control." The company has also committed to multiple buildouts of autoinjector and drug-device combination assembly infrastructure, in partnership with leading device manufacturers, at its campuses in Philadelphia and Rockford, Illinois. These upgrades are being introduced in phases over the next six months and are designed to expand both capacity and operational scale of its clinical-through-commercial capabilities. PCI plans to add a third autoinjector assembly line in 2027, which will bring its total U.S. capacity for autoinjector and device assembly to more than 250 million units annually. The lines are designed for high-speed, flexible manufacturing, with the ability to support multiple device formats, while dedicated prefilled syringe safety device capabilities add labeling and secondary packaging options. That growth aligns with what Roberts describes as a clear shift across the development pipeline, with more clinical programs - and ultimately commercial products - moving toward delivery formats such as prefilled syringes, pens, and autoinjectors. These systems support self-administration and are also enabling more decentralized clinical trial models, reducing the need for frequent site visits and potentially improving patient participation and retention. PCI's integrated model, spanning prefilled syringe manufacturing through final device assembly and packaging, is designed to support that continuity. The company's Packaging Centers of Excellence in Philadelphia and Rockford provide capacity for both oral solid dose and injectable products, along with cold chain storage and the ability to rapidly support programs at clinical or commercial scale. Across the two sites, available capacity includes approximately 40 million blister units, 70 million bottles, and 75 million vials annually. In conjunction with expanding its manufacturing platform, PCI is also investing in dedicated Development Centers of Excellence (CoE) in Bedford, New Hampshire, and León, Spain. These centers will support a range of development activities, including lyophilization, formulation, analytical services, drug-device combination development, long-acting injectables, and ophthalmic products, according to the company. The CoEs are designed to handle both highly potent and non-potent, small-molecule and biologic modalities across vials, prefilled syringes, and cartridges. The Bedford Development CoE is expected to be operational this May, with the León site slated for June. Andy Lundin has more than 10 years of experience in business-to-business publishing producing digital content for audiences in the medical and automotive industries, among others. He currently works as Senior Editor for Pharma Manufacturing and is responsible for feature writing and production of the podcast. His prior publications include MEDQOR, a real-time healthcare business intelligence platform, and Bobit Business Media. Andy graduated from California State University-Fullerton in 2014 with a B.A. in journalism. He lives in Long Beach, California. Recent Comments